Related Experiment Video

Updated: Mar 24, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016

David S Ettinger1, Douglas E Wood2, Wallace Akerley3

  • 1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Journal of the National Comprehensive Cancer Network : JNCCN
|March 10, 2016
PubMed

Insights

The 2016 National Comprehensive Cancer Network (NCCN) guidelines now prefer immune checkpoint inhibitors like nivolumab and pembrolizumab for advanced Non-Small Cell Lung Cancer (NSCLC) treatment. These immunotherapies offer better survival and fewer side effects than traditional chemotherapy.

Area of Science:

  • Oncology
  • Immunotherapy
  • Clinical Guidelines

Background:

  • Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality.
  • Traditional chemotherapy has limitations in efficacy and tolerability for advanced NSCLC.
  • Recent advancements in immunotherapy have shown promise in treating various cancers.

Purpose of the Study:

  • To summarize key updates from the 2016 NCCN Guidelines for NSCLC.
  • To highlight the recommended use of novel immunotherapeutic agents.
  • To provide guidance on second-line and subsequent therapy for metastatic NSCLC.

Main Methods:

  • Review of the 2016 NCCN Guidelines for NSCLC (Versions 1-4).
  • Focus on recommendations for immunotherapeutic agents, specifically nivolumab and pembrolizumab.
  • Analysis of comparative data against docetaxel for efficacy and safety.

Main Results:

  • Immune checkpoint inhibitors (nivolumab, pembrolizumab) are recommended as preferred agents for second-line and beyond therapy in metastatic NSCLC.
  • These agents are recommended for both squamous and nonsquamous NSCLC histologies.
  • Nivolumab and pembrolizumab demonstrated improved overall survival, response rates, and duration of response compared to docetaxel, with fewer adverse events.

Conclusions:

  • The 2016 NCCN guidelines reflect a significant shift towards immunotherapy in advanced NSCLC treatment.
  • Immune checkpoint inhibitors represent a preferred therapeutic option over docetaxel for subsequent lines of therapy.
  • These updates offer improved treatment strategies for patients with metastatic NSCLC, enhancing survival and quality of life.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

510
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Nursing Interventions II: Selecting and Classifying the Nursing Interventions01:29

Nursing Interventions II: Selecting and Classifying the Nursing Interventions

Creating and executing a nursing diagnosis helps nurses plan care and guide patient, family, and community interventions. They are developed based on a patient's physical evaluation and support measuring the outcomes. It is not recommended to select random interventions throughout the planning process. Instead, consider the following six essential factors when choosing interventions:
3.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K